Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NAV2 antisense RNA 2 (NAV2-AS2)
- Target
- NAV2-AS2
- Molecular classification
- Long non-coding RNA, RNA gene
01
Overview
NAV2 antisense RNA 2 is a long non-coding RNA (lncRNA) transcribed antisense to the NAV2 gene. It inhibits endothelial-to-mesenchymal transition (EndMT) by forming a sense-antisense RNA duplex with NAV2 messenger RNA, leading to increased NAV2 protein expression. This regulation helps downregulate Snail, a transcription factor driving EndMT, and thereby exerts anti-atherosclerotic effects with potential therapeutic relevance. The expression of NAV2-AS2 is reduced in atherosclerotic patient serum and animal models, and experimental overexpression in endothelial cells can prevent and treat diet-induced atherosclerosis in mouse models[1]. NAV2-AS2 is categorized as a long non-coding RNA involved in vascular biology, but no drugs or targeted therapies are currently associated with this molecule[1][5].
- Other names
- NAV2-AS2GeneCards ID: GC00U933615GeneCards ID: GC11M020066
02
Mechanism of action
RNA-based regulation (sense-antisense hybrid formation increases NAV2 stability and alters protein levels)
03
Biological functions
Regulation of endothelial-to-mesenchymal transition (EndMT)Regulation of NAV2 mRNA stabilityModulation of vascular cell phenotype
04
Disease associations
Cardiovascular disease (notably atherosclerosis)
05
Biomarkers
Decreased NAV2-AS2 expression in atherosclerotic serum and tissues may serve as a biomarker for disease state
Beyond the preview
Go deeper on NAV2 antisense RNA 2 (NAV2-AS2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAV2 antisense RNA 2 (NAV2-AS2).